Shaik Abjal Pasha, Shaik Asma Sultana, Majwal Ali Al, Faraj Achraf Al
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Prince Naif Health Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Cancer Res Treat. 2017 Apr;49(2):322-329. doi: 10.4143/crt.2016.091. Epub 2016 Jul 12.
The specific targeting of interleukin-4 receptor α (IL4Rα) receptor offers a promising therapeutic approach for inhibition of tumor cell progression in breast cancer patients. In the current study, the efficacy of superparamagnetic iron oxide nanoparticles conjugated with anti-IL4Rα blocking antibodies (SPION-IL4Rα) via polyethylene glycol polymers was evaluated in 4T1 breast cancer cells.
Cell viability, reactive oxygen species generation, and apoptosis frequency were assessed in 4T1 cancer cell lines following exposure to SPION-IL4Rα alone or combined with doxorubicin. In addition, immunofluorescence assessments and fluorimetrywere performed to confirm the specific targeting and interaction of the developed nanocarriers with IL4Rα receptors in breast cancer cells.
Blocking of IL4Rα receptors caused a significant decrease in cell viability and induced apoptosis in 4T1 cells. In addition, combined treatment with SPION-IL4Rα+doxorubicin caused significant increases in cell death, apoptosis, and oxidative stress compared to either SPION-IL4Rα or doxorubicin alone, indicating the enhanced therapeutic efficacy of this combination. The decrease in fluorescence intensity upon immunofluorescence and fluorimetry assays combined with increased viability and decreased apoptosis following the blocking of IL4Rα receptors confirmed the successful binding of the synthesized nanocarriers to the target sites on murine 4T1 breast cancerous cells.
These results suggest that SPION-IL4Rα nanocarriers might be used for successfulreduction of tumor growth and inhibition of progression of metastasis .
白细胞介素-4受体α(IL4Rα)受体的特异性靶向为抑制乳腺癌患者肿瘤细胞进展提供了一种有前景的治疗方法。在本研究中,评估了通过聚乙二醇聚合物与抗IL4Rα阻断抗体偶联的超顺磁性氧化铁纳米颗粒(SPION-IL4Rα)对4T1乳腺癌细胞的疗效。
在4T1癌细胞系中,单独或联合阿霉素暴露于SPION-IL4Rα后,评估细胞活力、活性氧生成和凋亡频率。此外,进行免疫荧光评估和荧光测定,以确认所开发的纳米载体与乳腺癌细胞中IL4Rα受体的特异性靶向和相互作用。
阻断IL4Rα受体导致4T1细胞的细胞活力显著降低并诱导凋亡。此外,与单独使用SPION-IL4Rα或阿霉素相比,SPION-IL4Rα与阿霉素联合治疗导致细胞死亡、凋亡和氧化应激显著增加,表明该联合治疗具有增强的疗效。免疫荧光和荧光测定中荧光强度的降低,以及IL4Rα受体阻断后活力增加和凋亡减少,证实了合成的纳米载体成功结合到小鼠4T1乳腺癌细胞的靶位点。
这些结果表明,SPION-IL4Rα纳米载体可能用于成功减少肿瘤生长和抑制转移进展。